
Operations Office

Telephone (507) 266-3549



Date: June 3, 2005

To: NCCTG Members

From: Lori K. Kelly
Protocol Development Coordinator

Re: N0177, A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Attached, please find the revised eligibility checklist for Study 2 or 3. Clarification has been added to the required characteristics section for Study 3 to reflect that Study 3 only pertains to patients **NOT** taking EIACs.

If you have any questions concerning this communication, please contact me at 507/266-3549.

Thank you.

Lkk
enclosure